PURPOSE: We determined the feasibility of a definitive trial comparing the effectiveness of group vs individual urotherapy for @entity1 with @entity1494 . MATERIALS AND METHODS: @entity1 6 to 10 years old with @entity1494 were recruited during the course of 1 year. Feasibility data on screening, eligibility, recruitment and protocol compliance rates were collected. @entity1 with high grade @entity3041 , @entity3025 or @entity4207 and those who had previously undergone urotherapy were excluded. @entity1 were randomized to 1-hour group urotherapy or 15-minute individual urotherapy. Symptoms and quality of life were measured using the Vancouver Nonneurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome Questionnaire and the Pediatric Incontinence Questionnaire at baseline and at 3 to 6 months of followup. Within/between group comparisons were conducted using t-tests. RESULTS: Of 455 screened @entity1 79 were eligible and 60 were recruited to participate. A total of 24 @entity1 randomized to group urotherapy and 25 randomized to individual urotherapy completed the pilot trial (6 undergoing group and 5 undergoing individual urotherapy withdrew from the study). Symptomology scores between group and individual urotherapy were not different at followup (mean    SD 14.7    7.9 vs 13.4    6.3, p = 0.54, 95% CI -5.4-2.8). Quality of life scores between @entity1 undergoing group and individual urotherapy at baseline differed (mean    SD 21.1    10.8 vs 31.0    14.3, p <0.01, 95% CI 2.7-7.3) but became similar at followup (21.0    14.2 vs 20.1    15.3, p = 0.84, 95% CI -9.4-7.6). Within group analyses demonstrated improvement in symptomology from baseline to followup in @entity1 undergoing group (mean    SD 3.6     7.6, p  =  0.03, 95% CI 0.4-6.8) and individual urotherapy (6.0    5.4, p <0.01, 95% CI  3.8-8.3). Within group quality of life analyses revealed improvement in  Pediatric Incontinence Questionnaire scores from baseline to followup in @entity1 undergoing individual urotherapy (p <0.01, 95% CI 5.0-16.9) only. CONCLUSIONS: Urotherapy, regardless of modality, effectively improved @entity1494 symptoms. A definitive randomized controlled trial is feasible, considering that a high recruitment rate (76%) for this population has been established.

A Pilot Randomized Controlled Trial Evaluating the Effectiveness of Group vs Individual Urotherapy in Decreasing Symptoms Associated with XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'Children'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder-bowel dysfunction'] @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis'] @entity3025 :: ('MESH:D014718', 'Disease') :: ['vesicoureteral reflux'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['learning disabilities']
@entity1494 :: (MESH:D001745,Disease) :: ['Bladder-Bowel Dysfunction']
